CERAMENT® G 体外释放庆大霉素对骨折相关感染中不同庆大霉素耐药水平细菌的抗菌作用
本研究在体外用全洗脱模型测定 CERAMENT® G 在 2 个月内释放庆大霉素的规律,并按欧洲抗菌药物敏感性试验委员会(EUCAST)标准,检测其对骨折相关感染中常见 4 种细菌、每种 4 株不同庆大霉素敏感度分离株的抑菌圈。结果显示 24 小时已释放 95% 的可用庆大霉素,2 个月时仍可检出;除 1 株最低抑菌浓度 > 1024 mg/L 的金黄色葡萄球菌外,其余分离株均敏感,抑菌圈与对数最低抑菌浓度相关。
要点
- CERAMENT® G 在 24 小时内释放 95% 的可用庆大霉素,2 个月时仍可检出。
- 对骨折相关感染常见 4 种细菌中,除 1 株最低抑菌浓度 > 1024 mg/L 的金黄色葡萄球菌外,其余分离株均显示抗菌活性。
- 抑菌圈与对数最低抑菌浓度相关,提示局部释放高浓度庆大霉素可覆盖部分全身用药耐药菌株。
核心结论
- CERAMENT® G 能在短时间内释放高水平庆大霉素,对全身用药耐药的细菌分离株仍有抗菌活性;作者认为这提出 EUCAST 全身用药折点是否适用于局部 CERAMENT® G 的问题,并指出需要标准化实验来制定局部抗生素使用指南以最终改善骨折相关感染治疗。
研究设计与样本
- 体外研究:用全洗脱模型在 2 个月内测定 CERAMENT® G 释放庆大霉素的规律,洗脱实验做 5 份、庆大霉素取样做 3 份、共 19 个时间点;抗菌活性按 EUCAST 纸片法测定,选用骨折相关感染中最常培养的 4 种细菌(金黄色葡萄球菌、表皮葡萄球菌、铜绿假单胞菌、阴沟肠杆菌),每种 4 株不同庆大霉素敏感度分离株,每株做 5 份。
主要发现
- 24 小时后已释放全部可用庆大霉素的 95%,2 个月时仍可检测到庆大霉素。
- CERAMENT® G 对所有细菌种类均显示抗菌活性,仅 1 株最低抑菌浓度 > 1024 mg/L 的金黄色葡萄球菌不敏感。
- 不同细菌分离株的抑菌圈与对数最低抑菌浓度相关。
关键数值与推荐
- 按 EUCAST 标准将每株分离株的敏感度分为 4 组:完全敏感(最低抑菌浓度 0.064 至 4 mg/L)、轻度耐药(最低抑菌浓度 4 至 16 mg/L)、中度耐药(最低抑菌浓度 8 至 96 mg/L)、高度耐药(最低抑菌浓度 24 至 1024 mg/L),具体取决于每种微生物。
- 抑菌圈与对数最低抑菌浓度之间按每种细菌计算非线性回归统计。
临床怎么用
- 作者指出 CERAMENT® G 的局部庆大霉素浓度远高于全身给药,似乎对全身可达浓度庆大霉素无效的某些细菌菌株有效。
- 作者认为从骨折相关感染患者中分离出对全身给药浓度庆大霉素耐药的细菌时,CERAMENT® G 可能仍然有效。
- 作者认为需要标准化实验测定骨折相关感染治疗中的局部抗生素抗菌活性,以形成局部抗生素使用指南并最终改善骨折相关感染治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fracture-related infection is a serious complication after trauma. CERAMENT® G combines dead-space management with local release of gentamicin in a single-stage procedure. Bacterial resistance against antibiotics is increasing. The local effect of CERAMENT® G on bacteria resistant to systemically administered gentamicin is unknown. QUESTIONS/PURPOSES: (1) What is the in vitro elution pattern of gentamicin from CERAMENT® G using a full washout model? (2) What is the in vitro antimicrobial activity (zone of inhibition) of CERAMENT® G against bacterial isolates found in fracture-related infection with different susceptibility levels toward gentamicin? METHODS: Elution of gentamicin from CERAMENT® G was determined in vitro over a period of 2 months. Elution experiments were performed in fivefold, with gentamicin being sampled in threefold at 19 different timepoints within 2 months. Antimicrobial activity was determined using the four most-frequently cultured bacterial species found in fracture-related infection: Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, and Enterobacter cloacae . For each of the species, four different isolates with a different susceptibility to gentamicin were used. According to the European Committee on Antimicrobial Susceptibility Testing, the susceptibility of each isolate was classified into four different groups: fully susceptible (minimum inhibitory concentration 0.064 to 4 mg/L), minimally resistant (minimum inhibitory concentration 4 to 16 mg/L), moderately resistant (minimum inhibitory concentration 8 to 96 mg/L), and highly resistant (minimum inhibitory concentration 24 to 1024 mg/L), depending on each organism. The antimicrobial activity of CERAMENT® G was determined according to the European Committee on Antimicrobial Susceptibility Testing disk protocol. The experiment was performed in fivefold for each isolate. The zone of inhibition was compared between each bacterial isolate and within each of the four separate species. Nonlinear regression statistics were calculated between the zone of interest and logarithmic minimum inhibitory concentration for each bacterial species. RESULTS: After 24 hours, 95% of all available gentamicin was eluted, and gentamicin was still detectable after 2 months. CERAMENT® G showed antimicrobial activity against all bacterial species; only S taphylococcus aureus (with a minimum inhibitory concentration > 1024 mg/L) was not susceptible. The zone of interest of the different bacterial isolates was correlated with the logarithmic minimum inhibitory concentration. CONCLUSION: CERAMENT® G offers a bone substitute capable of releasing high levels of gentamicin within a short period of time. This study shows that CERAMENT® G has antimicrobial activity against bacterial isolates that are resistant to gentamicin when systemically administered. This finding raises the question of whether European Committee on Antimicrobial Susceptibility Testing cutoff points for systemic application are useful for the use of local CERAMENT® G. Standardized experiments to determine local antibiotic antimicrobial activity in fracture-related infection treatment are needed to form guidelines for the use of local antibiotics and ultimately improve fracture-related infection treatment. CLINICAL RELEVANCE: Local concentrations of gentamicin with CERAMENT® G are much higher than when systemically administered. It seems effective against certain bacterial strains that are not affected by systemically reachable concentrations of gentamicin. CERAMENT® G might still be effective when bacteria that are resistant to systemically administered concentrations of gentamicin are occulated from patients with fracture-related infection.
引用
- Bezstarosti H, Van Lieshout EMM, Van den Hurk MJB, et al. In Vitro Elution of Gentamicin from CERAMENT® G Has an Antimicrobial Effect on Bacteria With Various Levels of Gentamicin Resistance Found in Fracture-related Infection. Clin Orthop Relat Res. 2024. PMID: 38289704. doi:10.1097/CORR.0000000000002975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。